Why is Interstitial Pneumonitis Relevant to Cancer Patients?
Cancer patients are at a higher risk for developing IP due to their treatment regimens. Chemotherapeutic agents, radiation therapy, and newer treatments like immunotherapy can all contribute to lung inflammation. Recognizing and managing IP in cancer patients is crucial, as it can significantly impact their overall prognosis and quality of life.
